Nano-based systems and biomacromolecules as carriers for metallodrugs in anticancer therapy

38Citations
Citations of this article
53Readers
Mendeley users who have this article in their library.

Abstract

Since the discovery of cisplatin and its potency in anticancer therapy, the development of metallodrugs has been an active area of research. The large choice of transition metals, oxidation states, coordinating ligands, and different geometries, allows for the design of metal-based agents with unique mechanisms of action. Many metallodrugs, such as titanium, ruthenium, gallium, tin, gold, and copper-based complexes have been found to have anticancer activities. However, biological application of these agents necessitates aqueous solubility and low systemic toxicity. This minireview highlights the emerging strategies to facilitate the in vivo application of metallodrugs, aimed at enhancing their solubility and bioavailability, as well as improving their delivery to tumor tissues. The focus is on encapsulating the metal-based complexes into nanocarriers or coupling to biomacromolecules, generating efficacious anticancer therapies. The delivery systems for complexes of platinum, ruthenium, copper, and iron are discussed with most recent examples.

Cite

CITATION STYLE

APA

Poursharifi, M., Wlodarczyk, M. T., & Mieszawska, A. J. (2019, January 1). Nano-based systems and biomacromolecules as carriers for metallodrugs in anticancer therapy. Inorganics. MDPI Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/inorganics7010002

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free